Panacur by is a Animal medication manufactured, distributed, or labeled by Schering Corporation, Intervet Production S.A., Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd, Intervet Mexico S.A. de C.V.. Drug facts, warnings, and ingredients follow.
Panacur® (fenbendazole) Paste 10% contains the active anthelmintic, fenbendazole. The chemical name of fenbendazole is methyl 5-(phenylthio)-2-benzimidazole carbamate.
The chemical structure is:
Each gram of Panacur® (fenbendazole) Paste 10% contains 100 mg of fenbendazole and is flavored with artificial apple-cinnamon liquid.
Panacur® (fenbendazole) Paste 10% is indicated for the control of large strongyles (Strongylus edentatus, S. equinus, S. vulgaris), encysted early third stage (hypobiotic), late third stage and fourth stage cyathostome larvae, small strongyles, pinworms (Oxyuris equi), ascarids (Parascaris equorum), and arteritis caused by fourth stage larvae of Strongylus vulgaris in horses.
Panacur® (fenbendazole) Paste 10% is approved for use concomitantly with an approved form of trichlorfon. Trichlorfon is approved for the treatment of stomach bots (Gasterophilus spp.) in horses. Refer to the manufacturer's label for directions for use and cautions for trichlorfon.
Side effects associated with Panacur® (fenbendazole) Paste 10% could not be established in well-controlled safety studies in horses with single doses as high as 454 mg/lb (1,000 mg/kg) and 15 consecutive daily doses of 22.7 mg/lb (50 mg/kg). Particularly with higher doses, the lethal action of fenbendazole may cause the release of antigens by the dying parasites. This phenomenon may result in either a local or systemic hypersensitive reaction. As with any drug, these reactions should be treated symptomatically.
Panacur® (fenbendazole) Paste 10% has been evaluated for safety in pregnant mares during all stages of gestation with doses as high as 11.4 mg/lb (25 mg/kg) and in stallions with doses as high as 11.4 mg/lb (25 mg/kg). No adverse effects on reproductivity were detected. The recommended dose for control of 4th stage larvae of Strongylus vulgaris, 4.6 mg/lb (10 mg/kg) daily for 5 consecutive days, has not been evaluated for safety in stallions or pregnant mares.
Regular deworming at intervals of six to eight weeks may be required due to the possibility of reinfection.
In the case of 4th stage larvae of Strongylus vulgaris, treatment and retreatment should be based on the life cycle and the epidemiology. Treatment should be initiated in the spring and repeated in the fall after a six month interval.
Optimum reduction of S. vulgaris infections is achieved by reducing the infectivity of the pastures. When horses are running on pasture, in temperate North America, maximum pasture infectivity occurs in October-December. If horses are removed from those pastures in January, pasture infectivity will decline to zero by July 1. Egg production of S. vulgaris is minimal from January through April, peaking in August and declining to minimal values in December.
**December 1, February 1, April 1, June 1, August 1, October 1.
The two treatments that are in bold type are the recommended periods when the 5 day treatment regimen for the control of the migrating larvae of S. vulgaris should be performed.
**For other areas in the world, retreatment periods for the migrating larvae of S. vulgaris may be different; consult with your veterinarian.
Panacur® (fenbendazole) Paste 10% is administered orally at a rate of 2.3 mg/lb (5 mg/kg) for the control of large strongyles, small strongyles, and pinworms. One syringe will deworm a 1,100 lb horse. For foals and weanlings (less than 18 months of age) where ascarids are a common problem, the recommended dose is 4.6 mg/lb (10 mg/kg); one syringe will deworm a 550 lb horse.
For control of encysted early third stage (hypobiotic), late third stage and fourth stage cyathostome larvae, and fourth stage larvae of Strongylus vulgaris, the recommended dose is 4.6 mg/lb (10 mg/kg) daily for 5 consecutive days; administer one syringe for each 550 Ibs body weight per day.
SEE PRECAUTIONS FOR RETREATMENT RECOMMENDATIONS.
intervet
panacur®
(fenbendazole)
Equine Dewormer 57 gram Paste 10% (100 mg/g)
FOR USE IN ANIMALS ONLY.
Net Wt. 57 g (2.01 oz)
WARNING: DO NOT USE IN HORSES INTENDED FOR HUMAN CONSUMPTION.
DIRECTIONS:
The contents of one syringe will deworm two 1,250 lb (568 kg) horses at the
standard dosage rate of 2.3 mg/lb (5 mg/kg). Refer to the carton for dosage and
full directions for use and for treatment of ascarids, encysted early third stage
(hypobiotic), late third stage and fourth stage cyathostome larvae and 4th stage
larvae of Strongylus vulgaris as well as for concomitant use with trichlorfon.
CONSULT YOUR VETERINARIAN FOR ASSISTANCE IN THE DIAGNOSIS,
TREATMENT AND CONTROL OF PARASITISM.
Each syringe contains 5.7 g of fenbendazole.
Keep this and all medication out of the reach of children.
Store at or below 25°C (77°F).
Manufactured by: DPT Laboratories,
San Antonio, TX 78215
Panacur is the property of Intervet International
B.V. or affiliated companies or licensors and is
protected by copyrights, trademark and other
intellectual property laws. Copyright © 2011
Intervet International B.V. All rights reserved.
NADA # 120-648, Approved by FDA 129670
UPC CODE
021784047159
PANACUR
fenbendazole paste |
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
PANACUR
fenbendazole paste |
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
Labeler - Schering Corporation (001317601) |
Establishment | |||
Name | Address | ID/FEI | Business Operations |
---|---|---|---|
Intervet Production S.A. | 771867553 | MANUFACTURE |
Establishment | |||
Name | Address | ID/FEI | Business Operations |
---|---|---|---|
DPT Laboratories, Ltd. | 832224526 | MANUFACTURE |
Establishment | |||
Name | Address | ID/FEI | Business Operations |
---|---|---|---|
Intervet Mexico S.A. de C.V. | 588215863 | API MANUFACTURE |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
PANACUR 81039083 1039083 Dead/Cancelled |
Hoechst Aktiengesellschaft 0000-00-00 |
PANACUR 73141362 1107717 Live/Registered |
HOECHST AKTIENGESELLSCHAFT 1977-09-15 |